Abiopharma

The Joint Corp. Board of Directors Authorizes an Additional $12 Million for Stock Repurchase Program

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

MindMed to Participate in Upcoming Investor Conferences

Charles River Laboratories Provides Update on Strategic Review

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Follow-up data for Kodiaks KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Tevas Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS